Enteryx reimbursement
This article was originally published in The Gray Sheet
Executive Summary
Results from Boston Scientific's ongoing U.S. and European gastrointestinal reflux disease treatment randomized placebo studies will be used to obtain private payor coverage. The 60-patient European study completed enrollment March 3, and enrollment for the 120-patient U.S. study is expected to conclude this summer. Both trials feature equal-sized treatment and placebo arms, with one-, three- and 12-month follow up. Enteryx recently received a CPT code for Medicare outpatient payment (1"The Gray Sheet" Nov. 24, 2003, In Brief)...
You may also be interested in...
GERD Treatments Need Further Study, BlueCross BlueShield Assessment Finds
Gastroesophageal reflux disease reimbursement trials should include control groups to discount placebo-effects, according to the BlueCross BlueShield Technology Evaluation Center
Boston Scientific Enteryx
Gastroesophageal reflux disease treatment gains newly assigned CPT code, permitting reimbursement under the hospital outpatient prospective payment system in 2004. The liquid polymer earned FDA approval in April (1"The Gray Sheet" April 28, 2003, p. 6)...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.